#1 Clinical Trials Search in Europe

Human Igg1 Monoclobal Antibody Against Sialyl-Lewis A

This article discusses ongoing clinical trials investigating the use of BNT321, a Human IgG1 Monoclonal Antibody Against Sialyl-Lewis A, in combination with mFOLFIRINOX for the treatment of resected pancreatic ductal adenocarcinoma. The trials aim to evaluate the safety, tolerability, and efficacy of this novel approach as adjuvant therapy following curative resection in patients with pancreatic cancer.

Table of Contents

What is BNT321?

BNT321 is a new medication being studied for the treatment of pancreatic cancer. It is classified as a human IgG1 monoclonal antibody that targets a specific molecule called sialyl-Lewis A[1]. In simpler terms, it’s a specially designed protein that can recognize and attach to certain markers found on pancreatic cancer cells.

How Does BNT321 Work?

BNT321 works by targeting pancreatic cancer cells that have the sialyl-Lewis A molecule on their surface. Once attached, it can help the body’s immune system recognize and attack these cancer cells. The medication is designed to work in two main ways:

  1. Antibody-dependent cell-mediated cytotoxicity (ADCC): This means BNT321 can signal immune cells to destroy the cancer cells it’s attached to.
  2. Complement-dependent cytotoxicity (CDC): BNT321 can also activate other proteins in the blood that can directly kill cancer cells[1].

Who Can Receive BNT321?

BNT321 is currently being studied for patients with pancreatic ductal adenocarcinoma (PDAC), which is the most common type of pancreatic cancer. Specifically, it’s being tested in patients who have had their tumor surgically removed (a procedure called resection) but are at risk of the cancer coming back[1].

To be eligible for the current study, patients must meet several criteria, including:

  • Be over 18 years old
  • Have had their pancreatic tumor completely removed through surgery
  • Have no evidence of cancer spread to other parts of the body
  • Be in generally good health and able to perform daily activities

How is BNT321 Administered?

BNT321 is given as a solution for infusion, which means it’s delivered directly into the bloodstream through an IV[1]. In the current study, it’s being tested in combination with a chemotherapy regimen called mFOLFIRINOX. The treatment schedule includes:

  • 24 weeks of mFOLFIRINOX with or without BNT321
  • For those receiving BNT321, an additional 24 weeks of BNT321 alone

Potential Benefits

The main goals of using BNT321 are to:

  • Prevent the cancer from coming back (improve disease-free survival)
  • Help patients live longer (improve overall survival)
  • Maintain or improve patients’ quality of life during treatment[1]

Safety and Side Effects

As BNT321 is still in the research phase, all of its potential side effects are not yet known. The current study is carefully monitoring patients for any adverse reactions. Some general side effects that may occur with antibody treatments like BNT321 include:

  • Infusion-related reactions
  • Fatigue
  • Nausea
  • Skin rashes

It’s important to note that the study is also looking at how BNT321 interacts with the chemotherapy drugs in mFOLFIRINOX, as this combination may have different side effects than either treatment alone[1].

Ongoing Research

BNT321 is currently being studied in a combined Phase I/II clinical trial. This means:

  • Phase I: Researchers are determining the safe dose of BNT321 to use with mFOLFIRINOX.
  • Phase II: Once the safe dose is established, researchers will compare mFOLFIRINOX alone to mFOLFIRINOX plus BNT321 to see if adding BNT321 improves outcomes for patients[1].

The study is also collecting detailed information on how BNT321 behaves in the body (pharmacokinetics), how it affects the immune system (pharmacodynamics), and whether patients develop antibodies against the drug (immunogenicity)[1].

It’s important to remember that while BNT321 shows promise, it is still an experimental treatment. More research is needed to fully understand its effectiveness and safety in treating pancreatic cancer.

Aspect Details
Trial Type Phase I/II, open-label, multicenter
Study Drug BNT321 (Human IgG1 Monoclonal Antibody Against Sialyl-Lewis A)
Combination Therapy mFOLFIRINOX
Target Condition Resected (R0 or R1) pancreatic ductal adenocarcinoma
Primary Objectives Phase I: Assess safety and determine recommended Phase II dose
Phase II: Evaluate efficacy by median disease-free survival
Key Eligibility Criteria – Confirmed PDAC
– Complete resection (R0 or R1)
– No evidence of metastatic disease
– Age >18 years
Treatment Duration 24 weeks of mFOLFIRINOX ± BNT321, followed by 24 weeks of BNT321 monotherapy in combination arm
Primary Endpoints Phase I: Safety and tolerability
Phase II: Disease-free survival

FAQ

  • What is BNT321? BNT321 is a Human IgG1 Monoclonal Antibody that targets Sialyl-Lewis A, which is being studied as a potential treatment for pancreatic cancer in combination with chemotherapy.
  • What type of cancer is being studied in these trials? The trials are focusing on pancreatic ductal adenocarcinoma (PDAC) that has been surgically removed (resected) with either R0 or R1 margins.
  • What is the main goal of the clinical trials? The main goals are to assess the safety and identify the recommended dose of BNT321 when combined with mFOLFIRINOX (Phase I), and to evaluate the efficacy of this combination compared to mFOLFIRINOX alone (Phase II) in improving disease-free survival.
  • Who is eligible to participate in these trials? Eligible participants are adults over 18 years old with confirmed pancreatic ductal adenocarcinoma who have undergone complete surgical resection and meet specific health criteria outlined in the trial protocol.
  • How long does the treatment last in the trial? In the Phase II part, treatment involves 24 weeks of mFOLFIRINOX with or without BNT321, followed by an additional 24 weeks of BNT321 monotherapy in the combination arm, for a total adjuvant therapy course of 48 weeks.

Ongoing Clinical Trials on Human Igg1 Monoclobal Antibody Against Sialyl-Lewis A

  • Study on the Safety and Effectiveness of mFOLFIRINOX with or without BNT321 for Patients with Resected Pancreatic Cancer

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Denmark France Germany Spain

Glossary

  • Pancreatic ductal adenocarcinoma (PDAC): A type of cancer that starts in the ducts of the pancreas, which is an organ located behind the stomach that helps with digestion and regulating blood sugar.
  • Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back.
  • mFOLFIRINOX: A combination chemotherapy regimen used to treat pancreatic cancer, consisting of multiple drugs given together.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. It's used to help the immune system fight cancer.
  • Sialyl-Lewis A: A molecule found on the surface of some cancer cells, which BNT321 is designed to target.
  • R0 resection: A surgery where all visible tumor is removed and the margins are clear of cancer cells when examined under a microscope.
  • R1 resection: A surgery where all visible tumor is removed, but cancer cells are found at the edges of the removed tissue when examined under a microscope.
  • Disease-free survival (DFS): The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Immunogenicity: The ability of a substance, such as a drug, to provoke an immune response in the body.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-mfolfirinox-with-or-without-bnt321-for-patients-with-resected-pancreatic-cancer/